BioSpace News Archive

Albany NY, United States: Advancement in scientific technology has led to development of new generation stents referred as flow diverters.

RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, announced the appointments, effective May 23, 2022, of Tracy Truong and Kelli Powell, as Regional Clinical Specialists for the West and Northeast Regions, respectively.

VISEN Pharmaceuticals announced positive top-line results from its pivotal phase 3 trial, a randomized, open-label, active-controlled trial that compared lonapegsomatropin, a once-weekly administered long-acting drug that delivers unmodified growth hormone, to a daily human growth hormone in children with growth hormone deficiency in China.

Epygenix Therapeutics, a clinical-stage biopharmaceutical company developing safe, effective, and patient-friendly drugs for rare and intractable forms of genetic epilepsy, announces the appointment of Lorianne Masuoka, MD as Chief Medical Officer.

Modra Pharmaceuticals announced that the company will present new data from its Phase 2b trial evaluating ModraDoc006/r, a boosted oral taxane therapeutic versus the standard-of-care IV chemotherapy docetaxel, in patients with metastatic Castration-Resistant Prostate Cancer at the upcoming ASCO General Annual Meeting held from June 3 – 7, 2022 virtually and in-person in Chicago, IL, USA.

Endotronix, Inc. announced positive data from the SIRONA 2 clinical trial evaluating safety and efficacy of its Cordella™ Pulmonary Artery Pressure Sensor System in New York Heart Association class III heart failure patients.

NanoString Technologies, Inc., a leading provider of life science tools for discovery and translational research, announced a seamless, cloud-based workflow that improves the spatial data analysis experience of customers using Illumina NextSeq™ 1000 and NextSeq™ 2000 sequencing systems and the GeoMx® Digital Spatial Profiler.

Axon Therapies, a private company focused on addressing a root cause of heart failure, announced positive early results from a roll-in cohort for their feasibility IDE trial, REBALANCE-HF.

Nemaura Medical, Inc., a medical technology company focused on commercializing a daily disposable wearable glucose sensor and supporting personalized digital coaching programs, announces that it has secured $5 million in non-dilutive funding though a clean debt facility with no warrants or convertible elements.

Ocugen, Inc. announced that the U.S. Food and Drug Administration lifted the clinical hold on the Company’s Phase 2/3 clinical trial, OCU-002, for COVAXIN™.